<DOC>
	<DOCNO>NCT00355134</DOCNO>
	<brief_summary>This study assess safety , tolerability efficacy two dose oral fingolimod compare placebo efficacy parameter patient relapsing-remitting multiple sclerosis ( RRMS ) .</brief_summary>
	<brief_title>Efficacy Safety Fingolimod ( FTY720 ) Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description>This randomize , multicenter , parallel-group study consist 2 phase : 24-month double-blind , randomize , multicenter , placebo-controlled , parallel-group study Extension phase consist dose-blinded period open-label period . In Core phase , patient randomize receive fix dose fingolimod ( 0.5 mg/day ) , fingolimod ( 1.25 mg/day ) placebo 24 month . For Extension phase , patient treat fingolimod Core phase continue treatment assign dose level , previously treat placebo Core phase re-randomized 1:1 ratio receive one two dos fingolimod ( 1.25 mg 0.5 mg ) . All patient extension receive blinded investigational drug : fingolimod 1.25 mg 0.5 mg capsule oral administration daily decision discontinue fingolimod 1.25 mg dose become effective subsequently patient switch open-label fingolimod 0.5 mg. With implementation Amendment 11 , 1.25 mg dose discontinue patient switch fingolimod 0.5 mg dose . With implementation Amendment 12 , patient treat Placebo fingolimod Core phase switch treatment 0.5 mg fingolimod per day . The Extension phase continue patient either discontinue transfer Study CFTY720D2399 ( NCT01201356 ; initiate September 2010 ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male female patient age 1855 diagnosis multiple sclerosis Patients relapsingremitting disease course Patients expand disability status scale ( EDSS ) score 05.5 Patients chronic disease immune system , malignancy , acute pulmonary disease , cardiac failure , etc . Pregnant nursing woman For inclusion extension phase patient complete 24 month core study without 24 month study drug . If patient discontinue study drug core study due adverse event , serious adverse event , laboratory abnormality etc . would exclude Extension Phase . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>fingolimod</keyword>
	<keyword>FTY720</keyword>
	<keyword>relapsing-remitting multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
</DOC>